Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus

Newer therapies are needed for the treatment of status epilepticus (SE) refractory to benzodiazepines. Enhanced glutamatergic neurotransmission leads to SE, and AMPA receptors are modified during SE. Reducing glutamate release during SE is a potential approach to terminate SE. The neuropeptide somat...

Full description

Bibliographic Details

Published in:	Neurobiology of Disease
Main Authors:	Maxim Kozhemyakin, Karthik Rajasekaran, Marko S. Todorovic, Samuel L. Kowalski, Corinne Balint, Jaideep Kapur
Format:	Article
Language:	English
Published:	Elsevier 2013-06-01
Subjects:	Somatostatin Somatostatin type 2 receptors Glutamate Synaptic transmission Status epilepticus
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996113000867